Saturday 17 October 2026
Export ELMD’s income statement to Excel — free account
Electromed, Inc.
ELMD Healthcare Medical Devices
Electromed, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $73.8 million, up 15.3% from fiscal 2025. In the quarter to June 2026, revenue grew 11.6%, EPS grew 57.7% and free cash flow fell 25.2%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
27.42
0.61
−2.18%
Follow ELMD
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
30.88 | 19.19 | 27.22 | 25.31 |
+8 more quarters Free account |
P/S ratio |
4.74 | 2.68 | 3.50 | 3.09 | |
P/FCF ratio |
41.80 | 20.68 | 29.39 | 23.38 | |
P/Operating CF |
116.78 | 55.30 | 79.59 | 1,209.05 | |
P/B ratio |
6.48 | 3.91 | 5.30 | 4.57 | |
Price to Tangible BV |
6.52 | 3.94 | 5.35 | 4.61 | |
EV/Sales |
4.48 | 2.46 | 3.31 | 2.89 | |
EV/EBITDA |
22.09 | 12.16 | 17.72 | 16.20 | |
EV/Operating CF |
34.18 | 16.75 | 25.00 | 20.68 | |
EV/FCF |
39.49 | 18.97 | 27.85 | 21.90 | |
Quick Ratio |
4.21 | 4.43 | 4.27 | 4.46 | |
Current Ratio |
4.69 | 4.91 | 4.86 | 5.09 | |
Net Debt/EBITDA |
(4.99) | (4.19) | (3.56) | (4.82) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.23 | 1.28 | 1.28 | 1.29 | |
Operating CF/Net income |
0.88 | 1.16 | 1.10 | 0.08 | |
Capex/Depreciation |
(0.82) | (0.54) | (2.54) | (1.03) | |
Research and Development Expense of Revenue |
1.69% | 1.94% | 2.03% | 1.43% | |
Selling, General and Administrative Expense of Revenue |
57.33% | 56.61% | 57.23% | 60.91% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
3.92% | 4.55% | 3.47% | 2.71% | |
Graham Net Nets |
0.13 | 0.21 | 0.15 | 0.17 | |
Graham Number |
14.19 | 12.82 | 11.50 | 10.83 | |
Earnings Yield |
3.24% | 5.21% | 3.67% | 3.95% | |
Free Cash Flow Yield |
2.39% | 4.84% | 3.40% | 4.28% | |
Revenue per Share |
2.35 | 2.26 | 2.28 | 2.03 | |
Operating CF per Share |
0.36 | 0.42 | 0.37 | 0.02 | |
Capex per Share |
(0.03) | (0.02) | (0.08) | (0.03) | |
Free Cash Flow per Share |
0.34 | 0.40 | 0.29 | (0.01) | |
Cash per Share |
2.47 | 2.07 | 1.67 | 1.70 | |
Shareholders Equity per Share |
6.53 | 5.99 | 5.49 | 5.38 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.53 | 5.99 | 5.49 | 5.38 | |
Free Cash Flow |
2.77 | 3.32 | 2.37 | (0.10) | |
Working Capital |
45.15 | 40.00 | 36.19 | 35.80 | |
Capital Expenditures |
(0.22) | (0.15) | (0.66) | (0.27) | |
Net Current Asset Value |
45.08 | 39.92 | 36.10 | 35.69 | |
EV/EBIT |
23.80 | 13.47 | 19.90 | 18.41 | |
Capex to Sales |
0.01 | 0.01 | 0.03 | 0.02 | |
Price to Operating Income |
25.19 | 14.68 | 21.00 | 19.66 | |
| Other line items | |||||
Average Receivables |
28.02 | 26.32 | 24.77 | 23.66 | |
Average Payables |
2.66 | 2.24 | 1.91 | 2.46 | |
Average Inventory |
3.49 | 3.13 | 3.27 | 3.60 | |
Average Assets |
60.03 | 55.96 | 53.59 | 51.26 | |
Average Common Equity |
48.59 | 46.55 | 44.52 | 43.12 |
Columns are period end dates